CLINICAL TRIALS PROFILE FOR TESOFENSINE

Clinical Trials for Tesofensine

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00148512 ↗	A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With M	Completed	Boehringer Ingelheim	Phase 2	The primary objective of this exploratory study is to investigate the efficacy and safety of tesofensine in daily doses (from 0.125 mg to 1.0 mg) in comparison to placebo, over a 14-week treatment period in levodopa treated Parkinson patients with motor fluctuations.
NCT00153010 ↗	An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type	Completed	Boehringer Ingelheim	Phase 2	Objectives: The objective of this study will be to determine the safety, tolerability, drug blood levels, and efficacy of each of three doses of NS 2330 (Tesofensine) given once daily compared with placebo in patients with mild to moderate Dementia of the Alzheimer's Type.
NCT00394667 ↗	Effect of Tesofensine on Weight Reduction in Patients With Obesity.	Completed	NeuroSearch A/S	Phase 2	Purpose: To evaluate the efficacy on weight reduction, metabolic parameters and safety of tesofensine versus placebo in obese patients
NCT00428415 ↗	Effect of Tesofensine on Energy Balance in Humans.	Completed	NeuroSearch A/S	Phase 1/Phase 2	Purpose: To evaluate the effect of tesofensine on energy balance
NCT00481104 ↗	Evaluation of Long Term Safety of Tesofensine in Patients With Obesity	Completed	NeuroSearch A/S	Phase 2	Purpose of the study is to evaluate the long term safety of tesofensine in obese patients

Clinical Trial Conditions for Tesofensine

Condition Name

Condition Name
Intervention	Trials
Obesity	4
Hypothalamic Injury-induced Obesity (HIO)	1
Hypothalamic Obesity	1
Parkinson Disease	1

Condition MeSH

Condition MeSH
Intervention	Trials
Obesity	4
Syndrome	2
Prader-Willi Syndrome	2
Dementia	1

Clinical Trial Locations for Tesofensine

Trials by Country

Trials by Country
Location	Trials
United States	32
Canada	6
Germany	4
Denmark	4
United Kingdom	1

Trials by US State

Trials by US State
Location	Trials
Michigan	3
Oregon	1
Oklahoma	1
Ohio	1
North Carolina	1

Clinical Trial Progress for Tesofensine

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	9
Phase 1/Phase 2	2
Phase 1	2

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	10
Recruiting	2
Unknown status	1

Clinical Trial Sponsors for Tesofensine

Sponsor Name

Sponsor Name
Sponsor	Trials
Saniona	7
NeuroSearch A/S	3
Boehringer Ingelheim	2

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	13
Other	2